Announced details
Domestic sales in South Korea (outpatient prescription results) exceeded KRW 1 trillion cumulatively in April 2026. Tegoprazan products are sold in 22 countries.
RaQualia Pharma licensed tegoprazan to HK inno.N Corporation. HK inno.N Corporation and Eurofarma entered into a technology transfer agreement for tegoprazan in 2022. Under its licensing agreement with HK inno.N Corporation, the company holds the right to receive a portion of the revenue that HK inno.N Corporation receives from its partner.
HK inno.N Corporation: Headquartered in Osong, South Korea. Eurofarma Laboratórios S.A.: Headquartered in São Paulo, Brazil, and a major pharmaceutical company. ANVISA: Brazil’s Health Regulatory Agency.
Marketing authorization from ANVISA; GMP certification from ANVISA for tegoprazan drug substance
Brazil’s National Health Surveillance Agency (ANVISA)
HK inno.N Corporation’s Daejeo plant (location details: Not disclosed)
The company will receive a milestone payment and recognize it as business revenue in the fourth quarter of the fiscal year ending December 2026. The impact on consolidated results for the fiscal year ending December 2026 has already been incorporated into the consolidated earnings forecast for the year disclosed on 13 February 2026.
The company does not address Contract Value / Offering price.
HK inno.N Corporation website (Korean)
| Item | Details |
|---|---|
| Names of Products / Services Covered | tegoprazan, TREV |
| Counterparty | HK inno.N Corporation, Eurofarma Laboratórios S.A., Brazil’s National Health Surveillance Agency (ANVISA) |
| Counterparty overview | HK inno.N Corporation: Headquartered in Osong, South Korea. Eurofarma Laboratórios S.A.: Headquartered in São Paulo, Brazil, and a major pharmaceutical company. ANVISA: Brazil’s Health Regulatory Agency. |
| Relationship with the Company | RaQualia Pharma licensed tegoprazan to HK inno.N Corporation. HK inno.N Corporation and Eurofarma entered into a technology transfer agreement for tegoprazan in 2022. Under its licensing agreement with HK inno.N Corporation, the company holds the right to receive a portion of the revenue that HK inno.N Corporation receives from its partner. |
| Contract Date | 2022 (technology transfer agreement between HK inno.N Corporation and Eurofarma) |
| Applicable area | Erosive gastroesophageal reflux disease, Non-erosive gastroesophageal reflux disease, Gastric ulcers |
| Award/certification name | Marketing authorization from ANVISA; GMP certification from ANVISA for tegoprazan drug substance |
| Awarding / certifying body | Brazil’s National Health Surveillance Agency (ANVISA) |
| Location | HK inno.N Corporation’s Daejeo plant (location details: Not disclosed) |
| Usage history | Domestic sales in South Korea (outpatient prescription results) exceeded KRW 1 trillion cumulatively in April 2026. Tegoprazan products are sold in 22 countries. |
| Impact on Business Performance | The company will receive a milestone payment and recognize it as business revenue in the fourth quarter of the fiscal year ending December 2026. The impact on consolidated results for the fiscal year ending December 2026 has already been incorporated into the consolidated earnings forecast for the year disclosed on 13 February 2026. |
| Source | HK inno.N Corporation website (Korean) |
Items this document does not state (6)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Because the marketing authorization from ANVISA is expected to enable entry into the Brazilian market and advance business expansion in Latin America. The company will receive a milestone payment and recognize it as business revenue in the fourth quarter of the fiscal year ending December 2026.